Round 2 - EOI - Frequently Asked Questions


Can I contact the QGHA Business Team to ask questions about Round 2 while the Round 2 clinical project application process is underway?

Yes. The QGHA Business Team is here to help you with developing your application.  The Business Team have already met with a number of interested applicants to talk through their proposed projects. To get in touch with the QGHA Business Team, please email projects@qgha.org.

1


What are the respective budgets for Round 2 Clinical Implementation, Incubation, and Innovation Projects?

As a guide the budget for a single Clinical Implementation Project is up to $1million.
As a guide the budget for Clinical Incubation and Clinical Innovation Projects is approximately $1million across both streams.

2


3

Would it enhance the strength of my project if I were to include additional hospitals as recruitment sites?

As long as you can get clinical ownership or a clinical champion at each of the sites you include and support from the hospital management. Clinicians involved need to have ownership of the project and the project’s outcomes. Gate 2 focuses on Clinical Utility and is where we consider clinical ownership and sponsorship of the project.
Additional sites also come with additional site-specific ethics approvals, so please consider the impact this may have on your project.


If I'm not a practising clinician but want to apply in Round 2 can I only apply if I have a clinician lead?

For the Clinical Implementation and Incubation Project applications the lead must be a practising clinician within the clinical specialty area the project is targeting. 
For Clinical Innovation Project applications you do not have to have a practising clinician as the lead, but applications will need to note which hospitals, local research institutions and core Queensland Health functions will be approached to collaborate on the project.

4


5

What is the best genomic sequencing approach to employ for my project – Panel-based Sequencing, Whole Exome Sequencing or Whole Genome Sequencing?

There is no one size fits all answer to this question, as there are benefits to each of these approaches in terms of cost, turn-around time and comprehensiveness of the result generated. We are happy to discuss these approaches with you in the context of your project, to help you weigh up their relative merits. We can also direct you to project partners that can assist in sequencing and bioinformatics analyses.


If I am an industry group and would like to participate, should I apply for a clinical project?

Please make contact with the QGHA Business Team so we can speak about your involvement in Gate 3 “Partnerships”.

6


Who should I (as the Project Lead) approach to be my Project Sponsor?

The Project Sponsor should be a senior executive from within your organisation who is committed to supporting you to deliver the outcomes and benefits of your proposed project.
An example would be the director of the clinical department where you are based (which would demonstrate departmental buy-in for Gate 2); or a senior manager in the hospital who will actively support and champion the project.

7


I’m concerned about the high level of competition that may exist for the two Clinical Implementation Projects. What can I do to maximise the impact of my Expression of Interest?

It’s really important that applicants address the Gate 1: EOI criteria listed within the Executive Summary and Project Objectives sections of the Guidance Document.
The purpose of the Gate process is to provide applicants with the time and resources required to amend various aspects of their applications, maximising their value proposition.

8


Should I list all project investigators in my Expression of Interest including capability partners e.g. health economists?

No, not at this stage. Projects will not be assessed on collaborations in Gate 1. Collaborations, including capability partners will be addressed at Gates 2 (Clinical Utility) & 3 (Partners and Capability).
QGHA wants to make sure that partnerships are well planned and acknowledge that meaningful collaboration takes time to develop.
You may wish to mention the disciplines you are considering, but you don’t have to list the partners.

9


What is the scope of QGHAs Round 2 investment?

The aim of QGHAs Round 2 investment is to accelerate the adoption of genomics into everyday healthcare in Queensland through promoting genomics projects that improve patient care in the hospital/clinical setting.

10


Do QGHA intend to fund infrastructure as part of Round 2 funding and if not, how will any intended growth in service provision be matched by a growth in infrastructure availability?

QGHA’s Round 2 funding does not extend to funding new infrastructure.
Queensland Health has capital infrastructure programs, through which the Department, and Hospital and Health Services fund infrastructure. These can grow to accommodate the expansion or addition of new services.  The QGHA presents an opportunity to facilitate relationships and focus within these programs.
In Round 2 QGHA aims to realise these opportunities through using the Round 2 Clinical Projects to establish requirements and to potentially pilot infrastructure through clinical services
QGHA is focused on establishing suitable business-related evidence, and business cases with clear requirements for capability and infrastructure in the health and research systems.
The investment in infrastructure and/or services will be made in partnership with participating organisations, and at the discretion of Queensland Health.

11


The development of state-wide genomics services will inevitably require the collation of large amounts of data from various sources within and outside the healthcare system. How will this be planned and implemented?

Through the capability building program QGHA will work with Queensland Health core functions, such as eHealth Queensland, existing capability building workstream projects such as Genomic Information Management and new partners to determine requirements.
The current Gate 1 EOI process is for Round 2 Clinical Projects.  The process to determine the capability building program will commence in July 2018 and will result in commissioning activities to meet Queensland Health requirements.

12


On top of implementing the clinical outcomes of Round 2 projects across Queensland, will it also be possible for participating organisations to use project findings outside of Queensland’s healthcare system?

The answer to this question is context-dependent. Generally speaking the aims of the QGHA are to support better health outcomes for Queenslanders, and to make a contribution nationally and internationally to the field of genomics implementation. The application of QGHA findings in organisations outside the QGHA and Queensland Health would lie with those external organisations.

13


If a clinical partner provides clinical information required as “seed data for innovation”, what data will be available for continued innovation and development within the Queensland environment to continue this work?

At this point in the process it is not possible to answer this question as it is context dependent. We will work with Round 2 Clinical Project Applicants to develop this type of detail. Any data arrangements that emerge must align with Queensland Health’s standards and guidelines.

14


What types of organisations are eligible to lead the projects?

The Clinical Project Specifications within the EOI guidelines lists the essential criteria required in each Clinical Project Stream. 

15


We assume based on the statement on page 11 “Applicants should propose what is achievable within the funding and timeline of their nominated investment stream rather than overcommitting to improve the project’s chances of selection as Gate 4” that the solution presented will be within “$2 million for Clinical Implementation and $1 million to be spread across Clinical Incubation and Innovation activities” described on page 6 of the guidelines. Is this correct?

Yes. Please note that QGHA will fund up to $1million for each Clinical Implementation Project (two projects). 
Overall funding for projects may include QGHA investment and co-contribution from participating organisations either as investment capital or in terms of human resource or other in-kind contributions.

16


Is it expected that all listed applicants on any given project will contribute throughout its lifecycle (implementation and beyond) or can they be interchanged?

We expect clinical leadership to be maintained by an organisation throughout the course of the project. We appreciate that individual people may change during the project, and executive sponsorship and leadership from within participating organisations will go a long way to mitigating this risk.

17


How are Round 2 projects expected to interact with national initiatives (e.g. My Health Record)?

Many linkages are in place to maximise QGHA’s chances to collaborate, share learnings and make a contribution to other Genomics Alliances within Australia and Internationally, and with significant digital health initiatives beyond Queensland. The Australian Digital Health Agency and the Australian Genomics Health Alliance have formed a committee to investigate linkages between the two programs, and the QGHA expects an opportunity will emerge to make a contribution. The QGHA’s primary focus at this time is to work with key Queensland Health business functions like eHealth Queensland, and our Hospital and Health Services to ensure genomic information is managed safely, securely, and sequence results are used for the benefit of patients.

18


“Projects may be seeded from results from other Genomics Alliances within and outside Australia but will be applied in Queensland.” Is this relative to the data used in the project or the origin of the funding? Can you please elaborate?

QGHA is interested in the lessons learnt in these programs and applying the medical knowledge relating to the application of genomics within disease areas for detection (diagnosis), treatment and management in Queensland’s health system. QGHA’s prime function is to accelerate the adoption of applicable medical genomics in Queensland and we are keen to leverage investments made in other part of Australia in terms of knowledge, and matching this to priority and high impact applications in the Queensland health system.

19


Do we need to list Pathology Queensland (PQ) as a collaborator in the EOI?

No, not at this stage. Projects will not be assessed on collaborations in Gate 1.
Collaborations, including capability partners will be addressed at Gates 2 (Clinical Utility) & 3 (Partners and Capability). 

20